China Medical Technologies (中国医疗技术公司) received SFDA approval for its Leukemia BCR/ABL fusion gene detection FISH Probe. The probe uses DNA probes to detect Philadelphia translocation, a chromosomal abnormality associated with three forms of leukemia. Detecting Philadelphia translocation is a critical diagnosis and prognosis tool for selecting the different treatment protocols appropriate for three of the most common forms of leukemia. More details...

Stock Symbol: (NSDQ: CMED)